The RSI Indicator for DXR moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
DXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXR as a result. In 97 of 127 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for DXR turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 50 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
DXR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for DXR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.061) is normal, around the industry mean (4.961). P/E Ratio (5.574) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.143). Dividend Yield (0.013) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. DXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IART declined for three days, in 233 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IART as a result. In 74 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for IART turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 32 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
The Aroon Indicator for IART entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IART's RSI Oscillator exited the oversold zone, 28 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 181 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IART may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.919) is normal, around the industry mean (2.874). IART has a moderately low P/E Ratio (-136.944) as compared to the industry average of (2.324). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. IART’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
DXR | IART | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 59 | 91 | |
PRICE GROWTH RATING 1..100 | 73 | 65 | |
P/E GROWTH RATING 1..100 | 96 | 14 | |
SEASONALITY SCORE 1..100 | 42 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IART's Valuation (7) in the Medical Specialties industry is significantly better than the same rating for DXR (73). This means that IART’s stock grew significantly faster than DXR’s over the last 12 months.
IART's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXR (100). This means that IART’s stock grew similarly to DXR’s over the last 12 months.
DXR's SMR Rating (59) in the Medical Specialties industry is in the same range as IART (91). This means that DXR’s stock grew similarly to IART’s over the last 12 months.
IART's Price Growth Rating (65) in the Medical Specialties industry is in the same range as DXR (73). This means that IART’s stock grew similarly to DXR’s over the last 12 months.
IART's P/E Growth Rating (14) in the Medical Specialties industry is significantly better than the same rating for DXR (96). This means that IART’s stock grew significantly faster than DXR’s over the last 12 months.
| DXR | IART | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 79% |
| Advances ODDS (%) | N/A | 11 days ago 62% |
| Declines ODDS (%) | 1 day ago 73% | 2 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 70% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXR’s FA Score shows that 0 FA rating(s) are green while IART’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXR’s TA Score shows that 2 TA indicator(s) are bullish while IART’s TA Score has 4 bullish TA indicator(s).
DXR (@Pharmaceuticals: Other) experienced а -4.33% price change this week, while IART (@Medical/Nursing Services) price change was -10.13% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
DXR is expected to report earnings on Nov 12, 2026.
IART is expected to report earnings on Mar 03, 2027.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -3.09% | ||
| IART - DXR | 33% Poorly correlated | +4.10% | ||
| BWAY - DXR | 27% Poorly correlated | -4.51% | ||
| AVTR - DXR | 23% Poorly correlated | -0.64% | ||
| COO - DXR | 20% Poorly correlated | +4.54% | ||
| SHC - DXR | 20% Poorly correlated | +2.03% | ||
More | ||||
A.I.dvisor indicates that over the last year, IART has been loosely correlated with RVTY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if IART jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To IART | 1D Price Change % | ||
|---|---|---|---|---|
| IART | 100% | +4.10% | ||
| RVTY - IART | 49% Loosely correlated | +0.48% | ||
| CNMD - IART | 48% Loosely correlated | +4.95% | ||
| MTD - IART | 44% Loosely correlated | +0.40% | ||
| A - IART | 43% Loosely correlated | -2.17% | ||
| AZTA - IART | 43% Loosely correlated | -2.04% | ||
More | ||||